Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

— First anti-PD-1 antibody from China to receive BTD

SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and
commercialization of novel therapies, announced today that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation